Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals (KNSA) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. ET. A live webcast of the presentation will be available on Kiniksa's website, with replays accessible within 48 hours post-event. The firm focuses on developing therapeutic medicines for diseases with significant unmet needs, featuring assets like ARCALYST® and mavrilimumab. For more details, visit www.kiniksa.com.

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40^th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST^® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ® Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com

FAQ

When is Kiniksa Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

Kiniksa Pharmaceuticals will present on January 10, 2022, at 1:30 p.m. ET.

How can I watch Kiniksa's presentation at the J.P. Morgan Healthcare Conference?

You can watch Kiniksa's presentation via a live webcast on their website.

What are some key assets of Kiniksa Pharmaceuticals?

Kiniksa's key assets include ARCALYST®, mavrilimumab, vixarelimab, and KPL-404.

What is the focus of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals focuses on developing therapeutic medicines for diseases with significant unmet medical needs.

Where can I find more information about Kiniksa Pharmaceuticals?

More information can be found on Kiniksa's website at www.kiniksa.com.